AL-07. Modern approaches to predicting post-transplant relapse of acute myeloid leukemia in children

Cellular Therapy and Transplantation

article

Zhemal Z. Rakhmanova¹  Olesya V. Paina¹  Ildar M. Barkhatov¹  Ilya V. Kazantsev¹  Ayrat M. Sadykov¹  Svetlana V. Razumova¹  Polina V. Kozhokar¹  Anastasiya S. Frolova¹  Liubov A. Tsvetkova¹  Elena V. Babenko¹  Tatyana L. Gindina¹  Alexander L. Alyanskiy¹  Elena V. Semenova¹  Ludmila S. Zubarovskaya¹ 

[1] RM Gorbacheva Research Institute, Pavlov University

关键词: Acute myeloid leukemia;    allogeneic hematopoietic stem cell transplantation;    minimal residual disease;    leukemic stem cells.;   

DOI  :  10.18620/ctt-1866-8836-2022-11-3-1-132

学科分类：肿瘤学

来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf

【 摘 要 】

Relapse of acute myeloid leukemia (AML) after allo-HSCT remains one of the main causes of treatment failure. Classical approaches for predicting the risk of AML recurrence after allo-HSCT are based on detection of minimal residual disease (MRD) by flow cytometry and molecular biology studies of recurrent aberrations. Recent studies of gene characteristic of leukemic stem cells (LSCs) defined at the onset of the disease have shown independent prognostic value for children with AML. Data on the pre-transplant level of LSC expression can serve as an additional tool in assessing the risk of post-transplant AML relapse. The aim of our study was to evaluate the influence of MRD status on the results of allogeneic HSCT (allo-HSCT) in children with AML, being determined both by classical methods and according to the genes characteristic of LSCs.

【 授权许可】

CC BY